Novartis' Exjade Recommended For Approval Under Broader Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Blood Products Advisory Committee agreed that data for the oral chelating agent from primarily thalassemia patients may be extrapolated to transfusional hemosiderosis.